Literature DB >> 10653020

Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients.

K Sennvik1, J Fastbom, M Blomberg, L O Wahlund, B Winblad, E Benedikz.   

Abstract

Alternative cleavage of the amyloid precursor protein (APP) results in generation and secretion of both soluble APP (sAPP) and beta-amyloid (Abeta). Abeta is the main component of the amyloid depositions in the brains of Alzheimer's disease (AD) patients. Using Western blotting, we compared the levels of alpha-secretase cleaved sAPP, beta-secretase cleaved sAPP and total sAPP, in cerebrospinal fluid (CSF) from 13 sporadic AD patients and 13 healthy controls. Our findings show significant amounts of beta-secretase cleaved sAPP in CSF. There was no statistically significant difference in the levels of beta-secretase cleaved sAPP between AD patients and controls. The levels of alpha-secretase cleaved sAPP and total sAPP were, however, found to be significantly lower in the AD patients than in the controls.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10653020     DOI: 10.1016/s0304-3940(99)00929-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  64 in total

Review 1.  Functions of the APP gene family in the nervous system: insights from mouse models.

Authors:  Dorothee Aydin; Sascha W Weyer; Ulrike C Müller
Journal:  Exp Brain Res       Date:  2011-09-20       Impact factor: 1.972

2.  Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain.

Authors:  Madepalli K Lakshmana; Crystal D Hayes; Steven P Bennett; Elisabetta Bianchi; Konda M Reddy; Edward H Koo; David E Kang
Journal:  FASEB J       Date:  2012-01-31       Impact factor: 5.191

Review 3.  Regulation of α-secretase ADAM10 expression and activity.

Authors:  Kristina Endres; Falk Fahrenholz
Journal:  Exp Brain Res       Date:  2011-10-04       Impact factor: 1.972

4.  ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons.

Authors:  Peer-Hendrik Kuhn; Huanhuan Wang; Bastian Dislich; Alessio Colombo; Ulrike Zeitschel; Joachim W Ellwart; Elisabeth Kremmer; Steffen Rossner; Stefan F Lichtenthaler
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

Review 5.  An overview of APP processing enzymes and products.

Authors:  Vivian W Chow; Mark P Mattson; Philip C Wong; Marc Gleichmann
Journal:  Neuromolecular Med       Date:  2010-03       Impact factor: 3.843

Review 6.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

7.  PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases.

Authors:  Mathéa Pietri; Caroline Dakowski; Samia Hannaoui; Aurélie Alleaume-Butaux; Julia Hernandez-Rapp; Audrey Ragagnin; Sophie Mouillet-Richard; Stéphane Haik; Yannick Bailly; Jean-Michel Peyrin; Jean-Marie Launay; Odile Kellermann; Benoit Schneider
Journal:  Nat Med       Date:  2013-08-18       Impact factor: 53.440

Review 8.  Role of APP Interactions with Heterotrimeric G Proteins: Physiological Functions and Pathological Consequences.

Authors:  Philip F Copenhaver; Donat Kögel
Journal:  Front Mol Neurosci       Date:  2017-01-31       Impact factor: 5.639

9.  Simultaneous characterization of glyco- and phosphoproteomes of mouse brain membrane proteome with electrostatic repulsion hydrophilic interaction chromatography.

Authors:  Huoming Zhang; Tiannan Guo; Xin Li; Arnab Datta; Jung Eun Park; Jie Yang; Sai Kiang Lim; James P Tam; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-01-04       Impact factor: 5.911

10.  A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts.

Authors:  Tapan K Khan; Thomas J Nelson; Vishal A Verma; Paul A Wender; Daniel L Alkon
Journal:  Neurobiol Dis       Date:  2009-02-20       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.